Artivion, Inc. (NYSE:AORT – Get Free Report) SVP Andrew Green sold 1,493 shares of Artivion stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $26.02, for a total transaction of $38,847.86. Following the transaction, the senior vice president directly owned 51,640 shares in the company, valued at $1,343,672.80. This trade represents a 2.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Artivion Trading Down 0.0%
Shares of Artivion stock traded down $0.01 during mid-day trading on Friday, hitting $25.61. The stock had a trading volume of 139,212 shares, compared to its average volume of 597,321. The firm has a 50-day moving average of $26.05 and a two-hundred day moving average of $29.23. The firm has a market cap of $1.25 billion, a P/E ratio of -365.49 and a beta of 1.25. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25.
Artivion (NYSE:AORT – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The firm had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Sell-side analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current year.
Hedge Funds Weigh In On Artivion
Analyst Ratings Changes
A number of equities analysts have recently weighed in on AORT shares. Citigroup reiterated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Citizens Jmp decreased their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings cut shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group boosted their price target on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.83.
Check Out Our Latest Stock Analysis on Artivion
About Artivion
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Read More
- Five stocks we like better than Artivion
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
